Merck and Syndax collaborate on entinostat/Keytruda combination trials

2 April 2015
merck-big

US pharma giant Merck & Co (NYSE: MRK) has entered into a clinical trial collaboration with Syndax Pharmaceuticals to evaluate the safety and efficacy of combining Syndax’s entinostat with Merck’s Keytruda (pembrolizumab).

The Phase Ib/II study will evaluate the combination in patients with either advanced non-small cell lung cancer or melanoma, and is expected to begin enrollment in the second half of 2015.

Entinostat is an oral, highly-selective distone deacetylase inhibitor granted Breakthrough Therapy Designation in combination with hormone therapy in advanced hormone receptor-positive breast cancer. It is currently in Phase III testing for this indication. Keytruda is a humanized monoclonal antibody blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical